并基因突变与肺癌：荟萃分析。
and Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.
机构信息
Department of Oncology, Tainan Hospital, Ministry of Health and Welfare, Tainan 700, Taiwan.
Department of Internal Medicine, National Cheng Kung University Hospital, College, Tainan 700, Taiwan.
出版信息
Medicina (Kaunas). 2020 Apr 27;56(5):212. doi: 10.3390/medicina56050212.
and are associated with many cancer types in addition to hereditary breast and ovarian cancers. However, their relation to lung cancer remains to be explored. Observation studies were systematically reviewed to explore the association of or with lung cancer. PubMed, MEDLINE [EBSCOhost], and relevant articles published up to 7 January 2020 were searched. Odd ratio (OR), standardized morbidity rate (SMR), and cancer-specific standardized incidence ratios (SIRs) were pooled together as relative risk (RR) estimates (95% confidence interval [CI], 0.66-1.40). Thirteen studies were included for analysis. Results showed that the RR of is 0.76 (95% CI, 0.48-1.19), the overall RR is 0.96 (95% CI, 0.66-1.40), and that of is 0.66 (95% CI, 0.41-1.05), indicating that it was not associated with lung cancer. With the limitation of the retrospective study design and severe heterogeneity, these results inform clinicians and relevant families that and mutation carriers have no increased risk of lung cancer.
此外， 与许多癌症类型有关，除了遗传性乳腺癌和卵巢癌。然而，它们与肺癌的关系仍有待探索。系统地回顾观察性研究，以探讨 或 与肺癌的关联。搜索了 PubMed、MEDLINE [EBSCOhost] 和截至 2020 年 1 月 7 日发表的相关文章。将比值比 (OR)、标准化发病比 (SMR) 和癌症特异性标准化发病比 (SIR) 汇总为相对风险 (RR) 估计值 (95%置信区间 [CI]，0.66-1.40)。 纳入了 13 项研究进行分析。结果表明， 的 RR 为 0.76(95%CI，0.48-1.19)，总 RR 为 0.96(95%CI，0.66-1.40)， 的 RR 为 0.66(95%CI，0.41-1.05)，表明 与肺癌无关。 由于回顾性研究设计的局限性和严重的异质性，这些结果告知临床医生和相关家庭， 突变携带者没有增加患肺癌的风险。
Zotero 插件